Rocket Pharma's shares soar after US FDA lets gene therapy trial resume
The drugmaker's shares were up 19% in midday trading after soaring more than 30% earlier Wednesday morning.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.